Composed of a team of research nurses and clinical research assistants, the TriHealth Hatton Research Institute's Oncology research team has many decades of experience in oncology research.
Clinical trials supported by our Oncology research team include cooperative group trials sponsored by the National Cancer Institute, studies through the Catholic Health Initiative, and Pharmaceutical Trials.
The term clinical trial is often raised in a hospital setting. It is likely that you will learn about possible clinical trials as you learn more about treatment options. Clinical trials occur in a secure and safe environment.
Clinical trials are experiments done in clinical research. Biomedical or behavioral research studies are designed to answer specific questions about new disease treatments (such as novel vaccines, drugs, dietary choices, dietary supplements and medical devices) and known interventions that warrant further study and comparison, but are not available for wide-spread use. This means that we are able to offer you options that may be new and cutting edge. Participating in a clinical trial it is ultimately your personal choice; however, clinical trials are conducted only after they have received health authority/ethics committee approval.
The TriHealth Hatton Research Institute's Oncology research team, and researchers at TriHealth’s Cancer Institute conduct important clinical trials targeting improvements in the prevention and treatment of specific kinds of cancer.
We screen ALL patients to determine who qualifies for clinical trials. Historically about five percent of our patients have qualified for trials.
A011801: For Patients with HER2 Positive Breast Cancer (Adjuvant Kadcyla +/- Tucatinib in Patients with HER2+ Residual Disease After Surgery (COMPASS HER2 RD): A Double-Blinded, Phase III Randomized Trial). Learn More
Contact Information
Principal Investigator: Apurva Mehta, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
A012103: For Patients with Triple Negative Breast Cancer (OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy). Learn More
Contact Information
Principal Investigator: Seerin Shatavi, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
Ascent-05: For Patients with Triple Negative Breast Cancer (Sacituzumab Govitecan-hziy + Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy). Learn More
Contact Information
Principal Investigator: Gina Matacia, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
Cambria-1: Early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (A Study of Camizestrant in ER+/ HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy). Learn More
Contact Information
Principal Investigator: Apurva Mehta, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
Cambria-2: For patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (Post-surgery Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/ HER2- Early Breast Cancer). Learn More
Contact Information
Principal Investigator: Apurva Mehta, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
S2010: A study monitoring symptoms to help young women take hormone therapy for Stage I-III breast cancer, ASPEN study (Randomized Trial of Active Symptom Monitoring + Patient Education vs. Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III HR+ Breast Cancer). Learn More
Contact Information
Principal Investigator: Brian Singeltary, DO
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
WF-2202: (Optimizing Psychosocial Intervention for Breast Cancer-related Sexual Morbidity: The Sexual Health and Intimacy Education (SHINE) Trial). Learn More
Contact Information
Principal Investigator: Seerin Shatavi, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
MagnetisMM-32: Newly Stage IV Cancer Dx, Solid or Heme Tumor (A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)). Learn More
Contact Information
Principal Investigator: Saulius Girnius, MD
Study Contact: Melinda O’Connor
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
A021806: (Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer). Learn More
Contact Information
Principal Investigator: Benjamin Kuritzky, MD
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
AZUR-2: (Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/ MSI-H Resectable Colon Cancer (AZUR-2)). Learn More
Contact Information
Principal Investigator: Benjamin Kuritzky, MD
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
CRDF-004: (Study of FOLFIRI+Bevacizumab or FOLFOX+Bevacizumab +/- Onvansertib for First-Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation). Learn More
Contact Information
Principal Investigator: Benjamin Kuritzky, MD
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
NRG-GI008: (Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America) Signatera ctDNA.). Learn More
Contact Information
Principal Investigator: Benjamin Kuritzky, MD
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
TP-CA-004 Gemini CRC: (Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients with CRC Using NGS Assays). Learn More
Contact Information
Principal Investigator: Benjamin Kuritzky, MD
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
DCP-001: Newly Stage IV Cancer Dx, Solid or Heme Tumor (Use of a Clinical Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)). Learn More
Contact Information
Principal Investigator: TriHealth Medical Oncology
Study Contact: TCBIResearch
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
CC-220-MM-002: (Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)). Learn More
Contact Information
Principal Investigator: Saulius Girnius, MD
Study Contact: Stacey Pitman
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
S2209: (A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance). Learn More
Contact Information
Principal Investigator: Saulius Girnius, MD
Study Contact: Stacey Pitman
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
NRG-CC008: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer. (A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA Carriers). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
NRG-GY019: (A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
GOG-3043: (A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
NRG-GY026: (A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with either Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
ZN-c3-004 TETON: (A Phase II, Open Label Study of WEE1 Inhibitor, ZN-c3 (Azenosertib), in Women With Recurrent or Persistent Uterine Serous Carcinoma). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
ZN-c3-005 DENALI: ***ACCRUAL ON HOLD*** (A Phase II, Open Label Study of WEE1 Inhibitor, ZN-c3 (Azenosertib), in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
GOG-3068 HOTT: (Phase III Randomized Trial of HIPEC with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial)). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Amanda Honaker
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
A151216 ALCHEMIST: (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Screening for Surgically Resected Early Stage NSCLC). Learn More
Contact Information
Principal Investigator: Andrew Parchman, MD
Study Contact: Peter (Eli) Wagner
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
A081801 ALCHEMIST Sub-Study: (Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study). Learn More
Contact Information
Principal Investigator: Andrew Parchman, MD
Study Contact: Peter (Eli) Wagner
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
Lung-MAP: (A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer). Learn More
Contact Information
Principal Investigator: Andrew Parchman, MD
Study Contact: Peter (Eli) Wagner
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
Lung-MAP Sub-Study S1900G: (Randomized Phase II Study of Capmatinib + Osimertinib +/- Ramucirumab in Patients with EGFR+, MET-Amplified Stage IV or Recurrent NSCLC). Learn More
Contact Information
Principal Investigator: Andrew Parchman, MD
Study Contact: Peter (Eli) Wagner
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
Lung-MAP Sub-Study S1900K: (Randomized Phase II Study of Tepotinib +/- Ramucirumab in Patients with MET Exon 14 Skipping Positive Stage IV or Recurrent NSCLC). Learn More
Contact Information
Principal Investigator: Andrew Parchman, MD
Study Contact: Peter (Eli) Wagner
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
TP-CA-002 Gemini NSCLC: (Tempus NSCLC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients with NSCLC Using NGS Assays). Learn More
Contact Information
Principal Investigator: Leanne Budde, MD
Study Contact: Akshitha Kasireddy
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
TP-CA-003 Sculptor: (Tempus Small Cell Lung Cancer (SCLC) Observational Study). Learn More
Contact Information
Principal Investigator: James F. Maher, MD, PhD
Study Contact: Akshitha Kasireddy
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
A092105: (Testing Nivolumab + Ipilimumab With or Without Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer). Learn More
Contact Information
Principal Investigator: Samer Alsidawi, MD
Study Contact: Alyssa Adams, CCRC
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
S2205 Ice Compress: (Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Emma Ohlhaut
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191 ComboMATCH: Solid Tumor Screening Trial (Molecular Analysis for Combination Therapy Choice (ComboMATCH). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-A3 ComboMATCH LGSOC Sub-study: Pancreatic, Tumor Agnostic (Palbociclib and Binimetinib in RAS-Mutant Cancers K/N/HRAS, non-BRAF V600E, or rare RAF fusions low grade serous ovarian (excludes NSCLC, CRC, melanoma). Learn More
Contact Information
Principal Investigator: Robert Neff, MD
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-A6 ComboMATCH JIT Sub-study: Locally advanced or Metastatic biliary tract cancer (FOLFOX +/- Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations RAS/RAF/MEK/ERK mutations, exclude BRAF V600E). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-E4 ComboMATCH JIT Sub-study: Prior Taxane Therapy (Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-E5 ComboMATCH JIT Sub-study: KRAS G12C Mutation (A Randomized Phase II Study of Sotorasib +/- Panitumumab in Advanced Solid Tumors KRAS G12C). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-N2 ComboMATCH JIT Sub-study: HR+, HER2-mBC, Inactivating NF1 Mutation (Phase 2 Trial of Fulvestrant +/- Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Inactivating or Inferred Inactivating NF1 Alterations). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-N4 ComboMATCH JIT Sub-study: Metastatic Ovarian or Endometrial (A Randomized Trial of Selumetinib +/- Olaparib in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers K/N/HRAS, BRAF, MEK1/2, inactivating NF1 mutation). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-N5 ComboMATCH JIT Sub-study: HER2 Amplified Non-breast Solid Tumor (A Randomized Trial of Neratinib +/- Palbociclib in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
EAY191-S3 ComboMATCH JIT Sub-study: Non-breast Solid Tumor With PTEN/AKT Mutations (Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors AKT1/2/3 mutation). Learn More
Contact Information
Principal Investigator: TCBI Medical Oncologist
Study Contact: Patrick Newbury
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
TRIDENT-1: Solid Tumor With NTRK1,2, or 3 Mutation (A Phase 2 Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK 1-3 Rearrangements (TRIDENT-1) ALK and ROS1 Cohorts closed to accrual). Learn More
Contact Information
Principal Investigator: Benjamin Kuritzky, MD
Study Contact: Akshitha Kasireddy
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005
KeyNote-B57 FujiFilm: (A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors). Learn More
Contact Information
Principal Investigator: James F. Maher, MD, PhD
Study Contact: Akshitha Kasireddy, MPH
Email For More Information: tcbiresearch@trihealth.com
Call For More Information: 513-865-1005